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P ostoperative pulmonary complications (PPCs) are associated with high mortality and long intensive 
care unit (ICU) stays in adults [1].  The PPC incidence 
in two studies of adult patients ranges from 5% to 33%,  
depending on the definition of PPCs,  the patients’ 
characteristics,  and the types of surgery [1 , 2].  The 
prevention of PPCs is important in children as well as 
adults.  The rate of reintubation after pediatric cardiac 
surgery has been reported to be approx.  6-9% [3 , 4].  
Little is known about the incidence of PPCs in children 
after cardiac surgery.
Some interventions to prevent PPCs are periopera-
tively provided in adults.  These include lung protective 
mechanical ventilation,  intermittent positive pressure 
breathing,  deep-breathing exercises,  intensive spirom-
etry,  and chest physiotherapy.  Among these interven-
tions,  the intraoperative strategy of lung protective 
mechanical ventilation with a low tidal volume,  high 
positive end expiratory pressure,  and recruitment 
maneuvers has been the only preventive method to 
show evidence of reducing the incidence of PPCs [5].  
However,  applying lung protective mechanical ventila-
tion for children undergoing cardiac surgery may be 
deleterious because of pulmonary hypertension,  single 
ventricle physiology,  and low cardiac output syndrome.
High-flow nasal cannula (HFNC) is a respiratory 
support device that can deliver heated and humidified 
gas at a higher rate than the patient’s inspiratory flow rate 
[6].  The 24-h use of HFNC significantly reduced the risk 
of reintubation in extubated adult patients compared to 
conventional oxygen therapy [7].  HFNC have been used 
for children with bronchiolitis,  in the interhospital 
transport of critically ill children,  and in the postextu-
bation period in neonates [8-11].  The use of HFNC has 
beneficial effects compared to conventional oxygen ther-
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apy in that it provides precise fractional oxygen delivery 
and mild positive airway pressure,  flushes the nasopha-
ryngeal dead space,  and reduces airway resistance [12-
15].  Moreover,  HFNC may be more comfortable for 
children than conventional oxygen therapy [16].
We therefore speculated that the use of HFNC could 
be a first-line oxygen therapy following extubation after 
pediatric cardiac surgery for the purpose of respiratory 
support.  We have planned the present study to deter-
mine the incidence of PPCs with the prophylactic appli-
cation of HFNC in extubated children who are sched-
uled to undergo pediatric cardiac surgery.  We 
hypothesize that the prophylactic use of HFNC will be 
associated with a low incidence of PPCs and that this 
therapy will be applicable for first-line oxygen therapy 
after pediatric cardiac surgery.
Methods
Design and study setting. This study is a sin-
gle-arm prospective interventional study.  We will con-
duct the study in a tertiary teaching hospital that has 
865 beds including 8 beds in the pediatric cardiac ICU.  
This trial is registered in the University Hospital 
Medical Information Network Individual Case Data 
Repository (UMIN000025494).
Ethics. The Institutional Review Board of 
Okayama University Hospital approved this study (no.  
1701-004).  We will obtain written informed consent from 
a parent or guardian of all of the subjects preoperatively.
Eligibility criteria. The inclusion criterion is: a 
child < 48 months old for whom cardiac surgery for 
congenital heart disease is planned.  The exclusion crite-
ria are: children who have undergone palliative surgery 
for cyanotic heart disease,  who have undergone surgery 
without cardiopulmonary bypass,  or whose elective car-
diac surgery has been canceled; the presence of a tra-
cheostomy,  an unplanned extubation,  or a craniofacial 
abnormality; or the clinical judgment of the physician.
Study interventions. The study intervention pro-
tocol is illustrated in Fig. 1.  The study intervention will 
start after extubation in subjects in the ICU.  If the sub-
ject was extubated in the operation room,  the interven-
tion will start just after the subject arrives at the ICU.  
The use of the high-flow nasal cannula (HFNC) 
(OptiflowTM Nasal High Flow; Fisher & Paykel 
Healthcare,  Tokyo,  Japan) will be prophylactically com-
menced just after extubation at a flow rate of 2 L/kg/min,  
at 37°C with a humidifier,  and with an adequate frac-
tion of inspiratory oxygen to achieve target oxygen sat-
uration (SpO2) ≥ 94%.  The nasal cannula size will be 
selected based on the patient’s weight and nasal size.  
The use of the HFNC will be continued for 24 h after 
extubation if intolerance does not occur.
If the patient is not tolerant to the HFNC with a flow 
rate of 2 L/kg/min,  we will reduce the flow rate to 
1 L/kg/min.  If intolerance occurs at the flow rate of 
1 L/kg/min,  we will reduce the flow rate to < 1 L/kg/
min or change the HFNC to conventional oxygen ther-
apy such as therapy using a facemask and a nasal can-
nula.  The selection criteria for noninvasive ventilation 
(NIV) or reintubation during the 24-h intervention 
period are the physician’s clinical judgment based on the 
observation of clinical signs of an increased respiratory 
rate (RR),  worsening gas exchange,  or patient intoler-
ance.  There will be no limitation of oxygen therapy 
after the 24-h intervention period.
Data collection. Investigators will collect the fol-
lowing data: age in months,  body weight,  gender,  Risk 
Adjusted classification for Congenital Heart Surgery 
(RACHS-1) category [17],  cardiac diagnosis,  type of 
surgery,  cardiopulmonary bypass time,  operation time,  
anesthesia time,  use of neuromuscular blockade agents 
during the ICU stay,  and duration of mechanical venti-
lation.  Duration of mechanical ventilation is defined as 
the period on mechanical ventilation from the induction 
of anesthesia to extubation in the operation room or ICU.
Endpoints. This study’s primary outcome is 
theprevalence of PPCs (as defined below) within 48 h 
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Initial HFNC setting
　Flow 2 L/kg/min
　Temperature 37℃
　100%  relative humidity
　FIO2 set to achieve SpO2≥94%
Deﬁned as failure
HFNC therapy starts just after extubation
Duration of 24 h
No limitation after 24 h of intervention
Patient’s intolerance (+) →Reduce ﬂow to 1 L/kg/min
Patient’s intolerance (+)
→Reduce ﬂow to less than 1 L/kg/min
　or change to conventional oxygen therapy
Clinician judgment
The selection criteria for NIV or reintubation during 24-h intervention periods is based 
on the clinical judgment of the physician
Fig. 1　 Study intervention protocol.  HFNC,  high-ﬂow nasal can-
nula; FIO2,  inspiratory oxygen fraction SpO2,  oxygen saturation of 
a peripheral artery; NIV,  noninvasive ventilation 
after extubation.  The secondary outcomes are the rein-
tubation rate within 48 h after extubation,  the rate of 
completion of 24-h HFNC,  the length of ICU stay,  the 
ratio of the partial pressure of arterial oxygen to the 
fraction of inspired oxygen (P/F ratio),  and HFNC-
related adverse events.
Definitions of endpoints. We define ‘PPCs’ as the 
combination of atelectasis and acute respiratory failure 
(ARF) after extubation.  A radiologist will assess atelec-
tasis by chest radiography on postextubation days 1 and 
2.  The definition of postextubation ARF is provided in 
Table 1.  This definition is a modification of a previous 
definition [18].  An investigator will diagnose ARF on 
postextubation days 1 and 2.  We will conclude that pro-
phylactic HFNC is effective if the prevalence of PPCs is 
< 10%.  This threshold was decided on the basis on rein-
tubation rates of 6-9% in previous reports [3 , 4].  The 
criteria for reintubation are: (1) worsened ARF 
(increased RR,  increased partial pressure of arterial 
carbon dioxide,  decreased SpO2),  (2) decreased con-
scious level,  (3) deterioration of cardiovascular func-
tions (cardiac arrest,  arrhythmia and heart failure),  and 
(4) clinical judgment of the attending clinicians.
We define the ‘completion rate of 24-h HFNC’ as the 
prevalence of children who complete 24 h of the pro-
phylactic use of HFNC without any treatment failure.  
‘Treatment failures’ are defined as: a flow rate of HFNC 
of < 1 L/kg/min or a change from HFNC to conven-
tional oxygen therapy due to the patient’s intolerance,  
the need for treatment escalation,  or the occurrence of 
HFNC-related adverse events.  ‘Treatment escalation’ is 
the need for NIV or reintubation.  NIV is initiated 
according to the clinical judgment of the physician 
based on clinical signs of increased RR,  worsening gas 
exchange or patient intolerance.
The P/F ratio will be measured during the 24-h 
HFNC period.  We will measure this parameter during 
the period of HFNC at the flow rate of 2 L/kg/min.
‘HFNC-related adverse events’ are defined as nasal 
ulcer,  pneumothorax,  and abdominal distension.  The 
bedside nurse will record the rate of these events during 
the 24-h HFNC period.
Statistical consideration. The prophylactic use of 
HFNC might have the potential to reduce the incidence 
of PPCs following extubation after pediatric cardiac 
surgery.  To investigate this possibility,  we will set the 
incidence of PPCs at < 10% as a threshold of the effec-
tiveness of prophylactic HFNC on the basis of the 
reported reintubation rates in children who underwent 
cardiac surgery (6-9%) [3 , 4].  We estimated that a sam-
ple size of 100 patients would be required to set the 
upper limit of the 95% confidence interval to > 16%.  An 
interim analysis is planned after the collection of data 
from 50 children.
The Shapiro-Wilk test will be used to assess normal-
ity.  Continuous data will be expressed as medians and 
their interquartile range (IQR) or as means and their 
standard deviation (SD).  Categorical data will be pre-
sented as percentages.  We will compare demographic 
data for children with PPCs and those without PPCs if 
the incidence of PPCs is > 10%.  The Wilcoxon rank sum 
test or unpaired-t-test will be used to compare continu-
ous data.  Pearson’s chi-square test will be used to com-
pare categorical data.  Time-to-event curves will be 
obtained by the Kaplan-Meier method.  P-values < 0.05 
will be considered significant.  All statistical analyses 
will be performed using statistical software (JMP® 12,  
SAS Institute,  Cary,  NC,  USA).
Discussion
This study is the first single-arm prospective inter-
ventional study aiming to determine the prevalence of 
PPCs following extubation after pediatric cardiac surgery 
under the condition of the prophylactic use of HFNC.
The definition of PPCs has not been established in 
adults or children.  In previous studies,  PPCs were 
defined as the development of at least one of the follow-
ing within 7-30 postoperative days: atelectasis,  respira-
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Table 1　 Deﬁnition of postextubation acute respiratory failure
1.  Increased RR for the patientʼs age+ the use of accessory respira-
tory muscle
RR>50 breaths per min (<1 year old)
RR>40 breaths per min (1︲4 years old)
2. Hypoxemic acute respiratory failure (type 1)
PaO2 <60 mmHg or SaO2 <90% (with FIO2 >0.5)
3.  Hypercapnic acute respiratory failure (type 2)
pH<7.35 with PaCO2 >50 mmHg
4. Mixed form of acute respiratory failure: both criteria 2 and 3
ʻPostextubation acute respiratory failureʼ is deﬁned by at least one 
of the criteria 1︲4.
FIO2,  inspiratory oxygen fraction;  PaCO2,  partial pressure of arte-
rial carbon dioxide; PaO2,  partial pressure of arterial oxygen; RR,  
respiratory rate; SaO2,  oxygen saturation.
tory failure,  pleural effusion,  pneumothorax,  broncho-
spasm,  respiratory infection,  aspiration pneumonitis,  
and acute respiratory distress syndrome [1 , 2 , 19].  We 
have selected atelectasis and ARF as PPCs in this study 
because they are the most common pulmonary compli-
cations in children after pediatric cardiac surgery.  We 
exclude pleural effusion and pneumothorax from the 
definition of PPCs because the incidences of these com-
plications are more likely to be affected by the surgical 
procedure during cardiac surgery than the method of 
postoperative respiratory support.
As noted above,  we speculate that the prophylactic 
use of HFNC might have the potential to reduce the 
incidence of PPCs following extubation after pediatric 
cardiac surgery.  We must set a threshold to investigate 
this hypothesis because this study has no control group.  
We finally decided that the prevalence of PPCs should 
be set to < 10% as a threshold of the effectiveness of pro-
phylactic HFNC on the basis of data including the rein-
tubation rate in children undergoing cardiac surgery in 
previous studies and on the basis of the prevalence of 
PPCs in adults (due to the lack of data for PPCs in chil-
dren).  As we noted earlier,  the rate of reintubation after 
pediatric cardiac surgery is approx.  6-9% [3 , 4].  
Among several surgical procedures,  cardiac surgery has 
the highest rate of PPCs in adult patients (39%),  much 
higher than the rate of 5% in general cohorts [4].  
Another study showed that the rate of atelectasis (17%) 
was ten times higher than the reintubation rate (1.7%) 
in adult patients following noncardiothoracic surgery 
[1].  We thus consider the 10% threshold reasonable for 
the incidence of PPCs in this study.
Trial status. Enrollment in the study was initi-
ated on April 1,  2017.
Acknowledgments.　We thank Professor Shiro Hinotsu at the Center 
for the Innovative Clinical Medicine in Okayama University Hospital for his 
assistance with the protocol design.
References
 1. Fernandez-Bustamante A,  Frendl G,  Sprung J,  Kor DJ,  Subramaniam B,  
Martinez Ruiz R,  Lee JW,  Henderson WG,  Moss A,  Mehdiratta N,  
Colwell MM,  Bartels K,  Kolodzie K,  Giquel J and Vidal Melo MF:  
Postoperative Pulmonary Complications,  Early Mortality,  and Hospital 
Stay Following Noncardiothoracic Surgery: A Multicenter Study by the 
Perioperative Research Network Investigators.  JAMA Surg (2017) 
52: 157-166.
 2. Canet J,  Gallart L,  Gomar C,  Paluzie G,  Vallès J,  Castillo J,  Sabaté S,  
Mazo V,  Briones Z and Sanchis J; ARISCAT Group: Prediction of post-
operative pulmonary complications in a population-based surgical cohort.  
Anesthesiology (2010) 113: 1338-1350.
 3. Gupta P,  Rettiganti M,  Gossett JM,  Yeh JC,  Jeﬀries HE,  Rice TB and 
Wetzel RC: Risk factors for mechanical ventilation and reintubation after 
pediatric heart surgery.  J Thorac Cardiovasc Surg (2016) 151: 451-458.
 4. Gaies M,  Tabbutt S,  Schwartz SM,  Bird GL,  Alten JA,  Shekerdemian LS,  
Klugman D,  Thiagarajan RR,  Gaynor JW,  Jacobs JP,  Nicolson SC,  
Donohue JE,  Yu S,  Pasquali SK and Cooper DS: Clinical Epidemiology 
of Extubation Failure in the Pediatric Cardiac ICU: A Report From the 
Pediatric Cardiac Critical Care Consortium.  Pediatr Crit Care Med (2015) 
169: 837-845.
 5. Futier E,  Constantin JM,  Paugam-Burtz C,  Pascal J,  Eurin M,  
Neuschwander A,  Marret E,  Beaussier M,  Gutton C,  Lefrant JY,  
Allaouchiche B,  Verzilli D,  Leone M,  De Jong A,  Bazin JE,  Pereira B 
and Jaber S; IMPROVE Study Group: A trial of intraoperative low-tid-
al-volume ventilation in abdominal surgery.  N Engl J Med (2013) 
369: 428-437.
 6. Lee JH,  Rehder KJ,  Williford L,  Cheifetz IM and Turner DA: Use of high 
ﬂow nasal cannula in critically ill infants,  children,  and adults: a critical 
review of the literature.  Intensive Care Med (2013) 39: 247-257.
 7. Hernández G,  Vaquero C,  González P,  Subira C,  Frutos-Vivar F,  
Rialp G,  Laborda C,  Colinas L,  Cuena R and Fernández R: Eﬀect of 
Postextubation High-Flow Nasal Cannula vs Conventional Oxygen 
Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical 
Trial.  JAMA (2016) 13: 1354-1361.  
 8. Hough JL,  Pham TM and Schibler A: Physiologic eﬀect of high-ﬂow 
nasal cannula in infants with bronchiolitis.  Pediatr Crit Care Med (2014) 
15: 214-219.
 9. Schlapbach LJ,  Schaefer J,  Brady AM,  Mayﬁeld S and Schibler A:  
High-ﬂow nasal cannula (HFNC) support in interhospital transport of criti-
cally ill children.  Intensive Care Med (2014) 40: 592-599.
10. Manley BJ,  Owen LS,  Doyle LW,  Andersen CC,  Cartwright DW,  
Pritchard MA,  Donath SM and Davis PG: High-ﬂow nasal cannulae in 
very preterm infants after extubation.  N Engl J Med (2013) 369: 1425-
1433.
11. Turnham H,  Agbeko RS,  Furness J,  Pappachan J,  Sutcliﬀe AG and 
Ramnarayan P: Non-invasive respiratory support for infants with bronchi-
olitis: a national survey of practice.  BMC Pediatr (2017) 17: 20.
12. Dewan NA and Bell CW: Eﬀect of low ﬂow and high ﬂow oxygen delivery 
on exercise tolerance and sensation of dyspnea.  A study comparing the 
transtracheal catheter and nasal prongs.  Chest (1994) 105: 1061-1065.
13. Shepard JW Jr and Burger CD: Nasal and oral ﬂow-volume loops in nor-
mal subjects and patients with obstructive sleep apnea.  Am Rev Respir 
Dis.  (1990) 142: 1288-1293.
14. Rubin S,  Ghuman A,  Deakers T,  Khemani R,  Ross P and Newth CJ:  
Eﬀort of breathing in children receiving high-ﬂow nasal cannula.  Pediatr 
Crit Care Med (2014)15: 1-6.
15. Nishimura M: High-ﬂow nasal cannula oxygen therapy in adults.  Journal 
of Intensive Care (2015) 3: 15-22.
16. Spentzas T,  Minarik M,  Patters AB,  Vinson B and Stidham G: Children 
with respiratory distress treated with high-ﬂow nasal cannula.  J Intensive 
Care Med (2009) 24: 323-328.
17. Jenkins KJ,  Gauvreau K,  Newburger JW,  Spray TL,  Moller JH and 
Iezzoni LI: Consensus-based method for risk adjustment for surgery for 
congenital heart disease.  J Thorac Cardiovasc Surg (2002)123: 110-118.
18. Muñoz-Bonet JI,  Flor-Macián EM,  Brines J,  Roselló-Millet PM,  
Cruz Llopis M,  López-Prats JL and Castillo S: Predictive factors for the 
outcome of noninvasive ventilation in pediatric acute respiratory failure.  
Pediatr Crit Care Med (2010) 11: 675-680.  
19. Pantel H,  Hwang J,  Brams D,  Schnelldorfer T and Nepomnayshy D: Eﬀect 
of Incentive Spirometry on Postoperative Hypoxemia and Pulmonary 
Complications After Bariatric Surgery: A Randomized Clinical Trial.  
JAMA Surg (2017) 152: 422-428.
196 Shioji et al. Acta Med.  Okayama　Vol.  72,  No.  2
